Immunovant stock is trading -22.62% below its average target price of $49.42 after marking a 6.2% during today's evening session. Analysts are giving the small-cap None company an average rating of buy and target prices ranging from $40.0 to $57.0 per share.
Immunovant has an elevated short interest of 10.2%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 5.49. Since 57.47% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Immunovant's rate of institutional ownership is 45.4%, which indicates a decent level of confidence in the stock. Based on these factors, Market Inference considers Immunovant to be the target of None.
Institutions Invested in Immunovant
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | FMR, LLC | 5% | 7,748,546 | $296,304,412 |
| 2023-09-30 | Vanguard Group Inc | 4% | 6,233,146 | $238,355,513 |
| 2023-09-30 | Blackrock Inc. | 3% | 4,131,665 | $157,994,876 |
| 2023-09-30 | Perceptive Advisors Llc | 3% | 3,814,691 | $145,873,790 |
| 2023-09-30 | State Street Corporation | 2% | 3,468,617 | $132,639,919 |
| 2023-09-30 | Deep Track Capital, Lp | 2% | 2,797,955 | $106,993,803 |
| 2023-09-30 | Darwin Global Management, Ltd. | 1% | 1,818,371 | $69,534,510 |
| 2023-09-30 | Logos Global Management LP | 1% | 1,600,000 | $61,184,002 |
| 2023-09-30 | Alpine Global Management, LLC | 1% | 1,252,474 | $47,894,607 |
| 2023-09-30 | Cormorant Asset Management, LP | 1% | 1,225,000 | $46,844,002 |
